Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029778

Enrollment

Unknown

Registered

2020-02-13

Start date

2020-02-14

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

TCM Group:herbal medicine and conventional treatment

QFPD decoction group:QFPD decoction and conventional treatment

SFJD capsuale group:SFJD capsuale and conventional treatment

control group:conventional treatment

Eligibility

Sex/Gender

All

Age

15 Years to 85 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria of Novel Coronavirus Pneumonia (COVID-19).

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, allergic to the research drug; 2. Combined with cardiovascular, liver, kidney and hematopoietic systems and other serious primary diseases, mental illness; 3. Those with observational factors affecting efficacy; 4. Those who do not meet the inclusion criteria, do not use the prescribed drugs, can not determine the efficacy or incomplete information and other effects of efficacy or safety judgment.

Design outcomes

Primary

Measure	Time frame
Length of hospital stay;fever clearance time;	—

Secondary

Measure	Time frame
Effective rate of TCM symptoms;antipyretic time;clearance time of COVID-19 in Nasopharyngeal swabs;blood gas analysis;CT scan;inflammatory cytokines in blood serum;	—

Countries

China

Contacts

Public ContactWei Zhang

Shuguang Hospital Affiliated to Shanghai University of TCM.

zhangw1190@sina.com+86 13601733045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026